Literature DB >> 775004

Plasma post-heparin lipolytic activity and triglyceride clearance in uremic and hemodialysis patients and renal allograft recipients.

S L Ibels, M F Reardon, P J Nestel.   

Abstract

In order to study mechanisms in the pathogenesis of hypertriglyceridemia in uremia, maintenance hemodialysis, and post-renal transplantation, plasma post-heparin lipolytic acitivity was measured and the kinetics of triglyceride removal were determined during infusions of triglyceride in patients from each of these groups and in healthy control subjects. In addition, plasma lipolytic activity was measured both during the course of a single hemodialysis treatment and in response to daily hemodialysis over a five-day period. The mean serum triglyceride level was significantly elevated and the mean plasma post-heparin lipolytic activity significantly reduced in all three groups. Post-heparin lipolytic activity in transplant recipients with a normal serum creatinine concentration was not significantly different from that in control subjects. Those transplant recipients with mildly impaired graft function had levels of post-heparin lipolytic activity comparable to those in patients with end-stage renal failure. Triglyceride clearance was significantly reduced in both the transplant recipients and in the uremic patients. During a single hemodialysis treatment with systemic heparinization plasma lipolytic activity decreased after the first hour. With daily hemodialysis, predialysis post-heparin lipolytic activity progressively declined after the second day. It is concluded that reduced post-heparin lipolytic activity and decreased triglyceride clearance contribute to the hypertriglyceridemia seen not only in uremic patients and in patients on maintenance hemodialysis but also in renal allograft recipients. Diminished lipolytic activity in hemodialysis patients may be in part due to heparin-induced depletion.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 775004

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  9 in total

1.  Lipoprotein-apolipoprotein changes in renal transplant recipients.

Authors:  Maurizio Cassader; Gianluca Ruiu; Roberto Gambino; Natalina Alemanno; Giorgio Triolo; Fabrizio Veglia; Gianfranco Pagano
Journal:  Lipids       Date:  2002-10       Impact factor: 1.880

2.  High-density lipoprotein in chronic renal failure and after renal transplantation.

Authors:  E Savdie; J C Gibson; J H Stewart; L A Simons
Journal:  Br Med J       Date:  1979-04-07

3.  [Low molecular weight heparin: how does it modify lipid metabolism in chronic hemodialysis patients?].

Authors:  H Schneider; Y Schmitt
Journal:  Klin Wochenschr       Date:  1991-10-18

Review 4.  Post-transplant dyslipidemia: Mechanisms, diagnosis and management.

Authors:  Arnav Agarwal; G V Ramesh Prasad
Journal:  World J Transplant       Date:  2016-03-24

Review 5.  Predictive and Prognostic Roles of Gut Microbial Variation in Liver Transplant.

Authors:  Hon Jen Wong; Wen Hui Lim; Cheng Han Ng; Darren Jun Hao Tan; Glenn K Bonney; Alfred W C Kow; Daniel Q Huang; Mohammad Shadab Siddiqui; Mazen Noureddin; Nicholas Syn; Mark D Muthiah
Journal:  Front Med (Lausanne)       Date:  2022-05-10

Review 6.  [Alterations of fat metabolism in renal disease - pathogenetic mechanisms (author's transl)].

Authors:  W H Hörl; M Hörl; A Heidland
Journal:  Klin Wochenschr       Date:  1982-04-01

Review 7.  [Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].

Authors:  C J Olbricht
Journal:  Klin Wochenschr       Date:  1991-08-01

Review 8.  Endocrine and metabolic abnormalities following kidney transplantation.

Authors:  W H Hörl; W Riegel; C Wanner; M Haag-Weber; P Schollmeyer; H Wieland; H Wilms
Journal:  Klin Wochenschr       Date:  1989-09-01

9.  Effect of exercise therapy on lipid parameters in patients with end-stage renal disease on hemodialysis.

Authors:  Lorenzo Gordon; Donovan A McGrowder; Yeiny T Pena; Elsa Cabrera; Marilyn Lawrence-Wright
Journal:  J Lab Physicians       Date:  2012-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.